Propanc Biopharma (NASDAQ:PPCB) Approves Stock Buyback Plan

Propanc Biopharma (NASDAQ:PPCB) announced that its board has initiated a stock buyback program on Thursday, July 2nd, RTT News reports. The company plans to buyback $500.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 15,243,902.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Propanc Biopharma Stock Performance

Propanc Biopharma stock traded up $0.33 during trading on Thursday, hitting $1.77. The company’s stock had a trading volume of 52,981,538 shares, compared to its average volume of 8,980,336. The stock’s fifty day moving average is $1.93 and its 200 day moving average is $5.22. Propanc Biopharma has a 1-year low of $1.30 and a 1-year high of $270.25. The stock has a market capitalization of $4.04 million, a price-to-earnings ratio of -0.07 and a beta of 3.49.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Propanc Biopharma

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.